Mature osteocytes express a high level of Sclerostin, a well-known marker of osteocyte differentiation.8 It has been reported that an elevated level of Sclerostin in peripheral blood is linked to poor prognosis in multiple myeloma patients.17 However, our results showed that A5 CM had a low level of Sclerostin and did not contribute to this issue. This evidence concerns the gene SOST and plasma cell myeloma.